...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Molecular engineering human hepatocytes into pancreatic beta cells for diabetes therapy
【24h】

Molecular engineering human hepatocytes into pancreatic beta cells for diabetes therapy

机译:将人类肝细胞分子工程化成胰腺β细胞用于糖尿病治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Type 1 (formerly "juvenile") diabetes is believed to be an autoimmune disease in which host immune cells fail to recognize the insulin-producing beta cells contained within pancreatic islets of Langerhans as being "self and inappropriately elect to destroy these critical insulin-producing cells. The traditional methods of treating type 1 diabetes are good, but not perfect. The studies reported by Sapir et al. (1) in this issue of PNAS suggest that new, more acceptable approaches to beta cell replacement may be feasible.
机译:人们认为1型(以前称为“青少年”)糖尿病是一种自身免疫性疾病,其中宿主免疫细胞无法将朗格汉斯胰岛中所含的胰岛素产生β细胞识别为“自我且不适当地选择破坏这些关键的胰岛素产生过程” Sapir等人(1)在本期PNAS上报道的研究表明,传统的治疗1型糖尿病的方法是好的,但并不完美。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号